Related references
Note: Only part of the references are listed.Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice
A. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Rapid Development of Candida krusei Echinocandin Resistance during Caspofungin Therapy
A. Forastiero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Invasive Candidiasis
Bart Jan Kullberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Single-Dose Oritavancin Versus 7-10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study
G. Ralph Corey et al.
CLINICAL INFECTIOUS DISEASES (2015)
Update on Antifungal Drug Resistance
David S. Perlin et al.
CURRENT CLINICAL MICROBIOLOGY REPORTS (2015)
FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Nicholas D. Beyda et al.
CLINICAL INFECTIOUS DISEASES (2014)
Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?
A. Fekkar et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2014)
Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections
G. Ralph Corey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Development of echinocandin-resistant Candida albicans candidemia following brief prophylactic exposure to micafungin therapy
M. A. Ruggero et al.
TRANSPLANT INFECTIOUS DISEASE (2014)
Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations
Barbara D. Alexander et al.
CLINICAL INFECTIOUS DISEASES (2013)
In Vivo Activity of Oritavancin in Animal Infection Models and Rationale for a New Dosing Regimen in Humans
Paul G. Ambrose et al.
CLINICAL INFECTIOUS DISEASES (2012)
Fractal Geometry and the Pharmacometrics of Micafungin in Overweight, Obese, and Extremely Obese People
Ronald G. Hall et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: an Analysis of the SIMPLIFI Trial
Lala M. Dunbar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Candida Species to Anidulafungin, Caspofungin, and Micafungin
M. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2011)
FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based Surveillance
Alicia J. Zimbeck et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
D. Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review
Hsin-Yun Sun et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Caspofungin-non-susceptible Candida isolates in cancer patients
Diamantis P. Kofteridis et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Echinocandin pharmacodynamics: review and clinical implications
Melanie W. Pound et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Breakthrough Invasive Candidiasis in Patients on Micafungin
Christopher D. Pfeiffer et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
A Multicenter, Double-Blind Trial of a High-Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis
Robert F. Betts et al.
CLINICAL INFECTIOUS DISEASES (2009)
The evolution of haploidy and diploidy
Sarah P. Otto et al.
CURRENT BIOLOGY (2008)
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model
D. Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2007)
Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Pharmacokinetics and pharmacodynamics of antifungals
David Andes
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2006)
A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation
B. Sirohi et al.
BONE MARROW TRANSPLANTATION (2006)
Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant
J Hiemenz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients
N de Wet et al.
CLINICAL INFECTIOUS DISEASES (2004)
The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy
NP Wiederhold et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2003)
Share Paper
